Gilead Raises Full-Year Sales Outlook as Quarterly HIV Sales Rise 18%
Gilead Sciences raised its full-year sales outlook. Third-quarter product sales rose 13%, driven by double-digit growth in its HIV franchise; adjusted earnings were $2.55 per share.
Story updates
08:06:40 PM UTC
SquawkNews
Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion Biktarvy Sales Increase
08:15:12 PM UTC
SquawkNews
Gilead Sciences Q3 adjusted EPS beats estimates on HIV growth; raises FY2026 sales outlook
By Deena BeasleyGilead Sciences NASDAQ:GILD hiked its full-year sales outlook on Thursday and reported third-quarter product sales rose 13%, driven by a double-digit percentage jump for its flagship HIV drug franchise.The company reported quarterly adjusted earnings of $2.55 per share on revenue of…